Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 30.80
+0.20 (0.65%)
Apr 20, 2026, 1:24 PM CST
Prince Pharmaceutical Revenue
In the year 2025, Prince Pharmaceutical had annual revenue of 1.06B TWD with 53.07% growth. Prince Pharmaceutical had revenue of 448.06M in the half year ending June 30, 2025, with 25.86% growth.
Revenue
1.06B
Revenue Growth
+53.07%
P/S Ratio
1.06
Revenue / Employee
5.03M
Employees
210
Market Cap
1.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.06B | 366.18M | 53.07% |
| Dec 31, 2024 | 690.03M | -63.30M | -8.40% |
| Dec 31, 2023 | 753.33M | 40.80M | 5.73% |
| Dec 31, 2022 | 712.53M | 271.45M | 61.54% |
| Dec 31, 2021 | 441.08M | 145.28M | 49.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.34B |
| Excelsior Biopharma | 898.26M |
| Anxo Pharmaceutical | 883.22M |
| DV Biomed | 794.18M |
| Winston Medical Supply | 700.07M |
| GeneFerm Biotechnology | 677.10M |
| Tien Liang BioTech | 511.79M |
| Bioray Biotech | 230.06M |